Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.

Risk of flare and severe flare over 52 weeks The risk of SLE flare over 52 weeks was not significantly reduced with belimumab 10 mg/kg versus placebo in either BLyS subgroup, though there was a trend towards significance for the BLyS < 2 ng/mL group ( Table 3 ).

also in 2,760 other papers